Geoffrey I. Shapiro

Broad Institute — United States

Medicine · Health Sciences

115h-index56.6kcitations2.0kworks0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(497), Cancer Genomics and Diagnostics(408), PARP inhibition in cancer therapy(300), Pancreatic and Hepatic Oncology Research(252), Advanced Breast Cancer Therapies(225)

Publications2.0k total

A Phase Ib Study of Sapacitabine and Olaparib in Patients with <i>BRCA1/2-</i> Mutated Metastatic Breast Cancer
Clinical Cancer Research·2025
Supplementary Figure S2 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Supplementary Table S1 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Supplementary Figure S1 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Supplementary Figure S6 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Supplementary Figure S4 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Supplementary Figure S3 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Data from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Supplementary Figure S5 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry
JCO Precision Oncology·2025Open Access
Supplementary Figure S7 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Supplementary Materials S1 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Supplementary Figure S8 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
2025Open Access
Supplementary Figures S1-S9 and Tables S1-S4. from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
Figure 5 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
Supplementary Data from A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
2025Open Access
Figure 1 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
Figure 2 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
Figure 3 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
Figure 7 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
page 1 of 102Next →

Frequent Co-authors

Pasi A. Jänne(9), Keith D. Wilner(9), Alan D. D’Andrea(9), D. Ross Camidge(8), Kwok‐Kin Wong(8), Leena Gandhi(7), Jeffrey W. Clark(7), Takeshi Shimamura(7), Scott J. Rodig(7), Eunice L. Kwak(6), Benjamin Solomon(6), Matthew Meyerson(6), Sai‐Hong Ignatius Ou(5), Marileila Varella‐Garcia(5), Jeffrey A. Engelman(5), James G. Christensen(5), A. John Iafrate(5), Yung‐Jue Bang(5), Bruce E. Johnson(5), Alice T. Shaw(4)